[1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors
The present invention relates to novel [1,2,4]triazolopyridine compounds with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.
1. A compound of general formula (I)
any of its stereoisomers or any mixture of its stereoisomers or a pharmaceutically acceptable salt thereof, wherein R is branched butyl.
2. The compound according to claim 1 , any of its stereoisomers or any mixture of its stereoisomers or a pharmaceutically acceptable salt thereof, wherein R is 1-methylpropyl, 2-methylpropyl, or tert-butyl.
3. The compound according to claim 1 , which is [(1S)-1-methylpropyl] 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.
4. The compound according to claim 1 , which is [(1R)-1-Methylpropyl] 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.
5. The compound according to claim 1 , which is [2-Methylpropyl] 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.
6. The compound according to claim 1 , which is Tert-butyl 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.
7. A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutically acceptable vehicle or excipient or pharmaceutically acceptable carrier(s).
8. The pharmaceutical composition according to claim 7 further comprising one or more other therapeutically active compound(s).
9. A method of treating dermal diseases or conditions, the method comprising administering to a person suffering from at least one of said diseases an effective amount of one or more compounds according to according to claim 1 , optionally together with a pharmaceutically acceptable carrier or one or more excipients, wherein the dermal diseases and conditions are selected from the group consisting of dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, psoriasis, acne, pruritis, eczema, COPD and asthma.
10. A pharmaceutical composition comprising a compound according to claim 2 together with a pharmaceutically acceptable vehicle or excipient or pharmaceutically acceptable carrier(s).